Innovative Cell Therapy Shows Promise in Treating ALS Patients
A novel cell therapy developed by Dr. Parmar shows promising safety and efficacy for ALS and other diseases, opening new horizons in regenerative medicine.
Recent advancements in cell therapy have demonstrated significant potential in addressing neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). Dr. Simrit Parmar, an associate professor at Texas A&M University College of Medicine and founder of biotech firm Cellenkos Inc., has developed a novel treatment approach utilizing umbilical cord blood-derived regulatory T cells (Tregs). These cells are engineered to modulate inflammation at the core of ALS and other conditions like aplastic anemia. Her therapy has been tested on numerous patients, with results indicating it is both safe and effective.
Parmar emphasizes the broader impact of her work, stating, "If successful, millions could benefit from a treatment that improves organ function systematically without significant side effects." The promising outcomes have led to a strategic partnership between Cellenkos and a leading Saudi medical center in Riyadh, marking the first US-Saudi clinical trial alliance in this area. The joint efforts aim to advance trials for aplastic anemia and graft-versus-host disease and eventually expand into ALS and cardiovascular disease research.
Her method is distinctive because it does not require matching donor to patient, can be scaled for mass manufacturing, and uses umbilical cord cells that pose fewer risks of exacerbated inflammation compared to adult-derived Tregs. Over the past year, her team has treated over 80 patients suffering from various conditions, including ALS, with notable improvements observed in some cases.
Notably, her technology has garnered attention in major medical journals, with articles published in NEJM Evidence demonstrating the treatment's safety and benefits. In April 2025, a study detailed how multiple infusions could slow or reverse disease progression in ALS patients, while a 2024 study showed prolonged blood and platelet independence in aplastic anemia patients.
Dr. Parmar aims to achieve FDA approval in the US within two years for certain diseases and continues to seek funding for larger ALS trials. Her work is recognized for its groundbreaking potential to transform treatment options for difficult-to-treat diseases.
This innovative cell therapy represents a significant step forward in regenerative medicine, offering hope for patients with currently untreatable conditions.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Monoclonal Antibody Treatment Significantly Reduces Hospitalizations in Infants with Bronchiolitis
A groundbreaking study reveals that a single dose of the monoclonal antibody nirsevimab can reduce bronchiolitis hospitalizations in infants under six months by nearly half, highlighting a new preventive approach against RSV infections.
FDA Approves First Blood Test for Alzheimer's Disease in the US
The US has approved the first blood test for Alzheimer's, enabling earlier detection through a simple blood analysis that measures specific proteins linked to the disease, potentially transforming diagnosis and treatment.
Post-sepsis Syndrome: Understanding the Impact on Brain and Body Recovery
Post-sepsis syndrome affects many survivors with lasting physical, cognitive, and psychological effects. Understanding and improving post-sepsis care can enhance long-term recovery and quality of life.
